Human antidiuretic hormone/vasopressin/arginine vasopressin,ADH/VP/AVP ELISA Kit

Code CSB-E09080h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
arginine vasopressin
Alternative Names
AVP ELISA Kit; ARVP ELISA Kit; VPVasopressin-neurophysin 2-copeptin ELISA Kit; AVP-NPII) [Cleaved into: Arg-vasopressin ELISA Kit; Arginine-vasopressin); Neurophysin 2 ELISA Kit; Neurophysin-II); Copeptin] ELISA Kit
Abbreviation
AVP
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
1.25 pg/mL-80 pg/mL
Sensitivity
0.312 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Neuroscience
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
             
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human ADH in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:1 Average % 83  
Range % 81-99  
1:2 Average % 95  
Range % 90-105  
1:4 Average % 85  
Range % 80-91  
1:8 Average % 92  
Range % 80-98  
Recovery
The recovery of human ADH spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 97 85-98  
EDTA plasma (n=4) 94 90-105  
             
             
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected  
80 2.567 2.502 2.535 2.393  
40 1.851 1.816 1.834 1.692  
20 1.301 1.243 1.272 1.130  
10 0.852 0.809 0.831 0.689  
5 0.532 0.514 0.523 0.381  
2.5 0.383 0.376 0.380 0.238  
1.25 0.247 0.239 0.243 0.101  
0 0.145 0.139 0.142    
Materials provided
  • A micro ELISA plate --- The 96-well plate has been pre-coated with an anti-human AVP antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
  • Two vials lyophilized standard ---Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
  • One vial Biotin-labeled AVP antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody.
  • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) ---Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
  • One vial Biotin-antibodyDiluent (15 ml/bottle) ---Dilute the Biotin-antibody.
  • One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution.
  • One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration.
  • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) ---Wash away unbound or free substances.
  • One vial TMB Substrate (10 ml/bottle) ---Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
  • One vial Stop Solution (10 ml/bottle) ---Stop the color reaction. The solution color immediately turns from blue to yellow.
  • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
  • An instruction manual
Materials not provided
  • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
  • An incubator can provide stable incubation conditions up to 37°C±5°C.
  • Centrifuge
  • Vortex
  • Squirt bottle, manifold dispenser, or automated microplate washer
  • Absorbent paper for blotting the microtiter plate
  • 50-300ul multi-channel micropipette
  • Pipette tips
  • Single-channel micropipette with different ranges
  • 100ml and 500ml graduated cylinders
  • Deionized or distilled water
  • Timer
  • Test tubes for dilution
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Human AVP ELISA Kit was designed for the quantitative measurement of Human AVP protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 1.25 pg/mL-80 pg/mL and the sensitivity is 0.312 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Specifically binds vasopressin.; Has a direct antidiuretic action on the kidney, it also causes vasoconstriction of the peripheral vessels. Acts by binding to vasopressin receptors (V1bR/AVPR1B, V1aR/AVPR1A, and V2R/AVPR2).
Gene References into Functions
  1. Serum copeptin concentrations did not vary between the pregnancies complicated by intrahepatic cholestasis of pregnancy and the healthy pregnancy control group. PMID: 28552021
  2. Copeptin appears to be an independent predictor of long-term mortality in a selected population of patients suspected for an acute coronary syndrome (ACS). In addition, copeptin may be considered as an early marker for the identification of patients at higher risk of the development of heart failure at long term in patients with acute chest pain. PMID: 29619130
  3. Increased levels of NT-proBNP seems to be a better biomarker of multidrug antihypertensive therapy requirement than CT-proAVP. PMID: 29190613
  4. High AVP expression is associated with gestational diabetes insipidus. PMID: 29378555
  5. Plasma concentration of copetin demonstrated associations with stroke occurrence in a West African cohort but was not associated with stroke severity or mortality. PMID: 29074065
  6. Data suggest that corticotrophin-releasing hormone (CRH) is able to stimulate copeptin release in healthy controls suggesting direct interaction of CRH/CRH-receptor signaling and vasopressin; these interactions appear to be altered in patients with pituitary disease; copeptin may be serum biomarker of altered CRH/CRH-receptor signaling in pituitary diseases. PMID: 28795329
  7. copeptin might have a potential role in the pathogenesis of restless legs syndrome and be a biomarker for this disease. PMID: 29148047
  8. Serum copeptin is a strong prognostic marker in both chronic obstructive pulmonary disease and acute heart failure. PMID: 29100503
  9. Hypothalamic suprachiasmatic nucleus -AVP-ir showed a significant negative correlation with age in the control group and in the male, but not in the female depression group. PMID: 28608287
  10. elevated plasma copeptin level is associated with an increased risk of heart failure (HF) and all-cause mortality in patients with HF. PMID: 28244638
  11. Resistin, but not copeptin levels are higher in acute ischemic stroke patients early after the stroke onset, than in age and gender matched stroke-free controls. Moreover, higher copeptin concentrations are predictive of poor short term functional outcome after ischemic stroke PMID: 28845746
  12. Cord blood copeptin concentration does not seem to be a promising marker of acute kidney injury in asphyxiated neonates. PMID: 27590891
  13. Elevated cord blood copeptin has high potential to become a routinely used biomarker for acute birth asphyxia and neonatal distress. PMID: 28351056
  14. Copeptin seems to be a promising independent biomarker for predicting the functional outcome and all-cause mortality within 3 months or 1 year after acute ischemic stroke--{REVIEW} PMID: 27904159
  15. Data suggest that men with type 1 diabetes and albuminuria had greater serum copeptin concentrations than men with normo-albuminuria. PMID: 27979439
  16. associated with significantly greater annual decline of glomerular filtration rate PMID: 27347674
  17. Copeptin levels are elevated in cerebral infarction, intracranial hemorrhage and subarachnoid hemorrhage but cannot be used in their differential diagnosis. PMID: 28164562
  18. High circulating copeptin and decline in glomerular filtration rate indicate greater risk of new onset chronic kidney disease. (Review) PMID: 28714397
  19. MR-proADM but not copeptin was significantly associated with prognosis of COPD exacerbations at 30 days. PMID: 28408815
  20. vasopressin and the glycopeptide - mediate physiological aggregation of the wild-type hormone precursor into secretory granules and the pathological fibrillar aggregation of disease mutants in the endoplasmic reticulum. PMID: 28122547
  21. The inability to clear misfolded proAVP with highly reactive cysteine thiols in the absence of Sel1L-Hrd1 ERAD causes proAVP to accumulate and participate in inappropriate intermolecular disulfide-bonded aggregates, promoted by the enzymatic activity of protein disulfide isomerase (PDI). PMID: 28920920
  22. High copeptin expression is associated with hypoxic-ischemic encephalopathy. PMID: 28931055
  23. Copeptin and osmolality were unaffected by sitagliptin treatment in type 2 diabetics with acute coronary syndrome. PMID: 27190088
  24. Copeptin levels are highest among acute myocardial infarction patients with glucose disturbances and predict an adverse prognosis in unadjusted analyses. PMID: 28118730
  25. high serum copeptin level is associated with disease severity and progression in IgA nephropathy. PMID: 28057871
  26. Copeptin was independently associated with an increased risk of incident stroke and CVD mortality in men with diabetes, but not in men without diabetes. PMID: 27312697
  27. Copeptin level at admission predicts final infarct size in STEMI patients. PMID: 27344134
  28. Copeptin (>/=9.6 pmol/L) was associated with significantly higher rates of myocardial injury and improved risk stratification in patients scheduled for noncardiac surgery with nonelevated preoperative troponin. PMID: 27870734
  29. It seems reasonable to indicate genetic testing of patients with isolated neurohypophyseal diabetes insipidus occurring during childhood or adolescence without a family history and without any identifiable cause as mutations of the AVP gene have been previously detected in children, who were thought to have idiopathic disease PMID: 27539621
  30. High plasma copeptin was associated with reduced insulin sensitivity and an increased risk for IFG/T2DM diabetes in this community-based cohort. Moreover, in men, allelic associations support a causal role for vasopressin in these disorders. PMID: 27049477
  31. Copeptin was elevated in, and independently predicted prognosis in Heart Failure PMID: 27523461
  32. Baseline measurements of Copeptin in patients undergoing renal sympathetic denervation (RDN) for resistant hypertension have no predictive value for response to RDN. PMID: 27775435
  33. Copeptin/UNa ratio may be used as a potential biomarker of Syndrome of Inappropriate Antidiuretic Hormone (SIADH in patients with tick-borne encephalitis (TBE) . Copeptin concentration is significantly higher in patients with TBE than in viral meningitis of other origin, especially in patients aged 18-34 and >49 years old. Copeptin does not differentiate TBE of mild and severe course. PMID: 27882774
  34. Copeptin and troponin T measurement could potentially improve the prehospital diagnostic and prognostic classification of patients with a suspected AMI. PMID: 27903076
  35. The early polyuria in recessive central diabetes insipidus contrasts with the delayed presentation in patients with monoallelic AVP mutations. PMID: 26565711
  36. Heart Failure is a complex syndrome with the differential integration of stimulatory and inhibitory inputs to the AVP/copeptin secretory system. PMID: 27396431
  37. copeptin may be a good biomarker for metabolic syndrome. PMID: 27928437
  38. The present study reports the genetic, clinical and biochemical characteristics of patients with Familial neurohypophyseal diabetes insipidus caused by five novel mutations in AVP. PMID: 27513365
  39. The combination of a clinical model with copeptin and NTproBNP, which are available in the Emergency Department, is able to prognose early mortality in patients with an episode of Acute Heart Failure. PMID: 28069402
  40. High Serum copeptin levels are associated with respiratory infections. PMID: 27171391
  41. A high serum copeptin concentration predicts transplant-free survival, particularly at 6 months, independently of liver-specific scoring systems in a heterogeneous population of hospitalized cirrhotic patients. PMID: 26502363
  42. A direct release of copeptin is not detectable from the human heart in acute myocardial infarction. PMID: 26864512
  43. plasma copeptin levels can be regarded for promising marker of severity of acute pulmonary embolism and show potential in risk stratification of these patients PMID: 26438275
  44. AVP gene mutation is associated with neurohypophyseal diabetes insipidus. PMID: 26208472
  45. Serum copeptin was found to be increasing significantly in cases of myocardial ischemia detected by myocardial perfusion scintigraphy. PMID: 26100831
  46. Serum copeptin is elevated in patients with acute pulmonary embolism. PMID: 26711465
  47. There was no significant difference in serum copeptin between patients with vasovagal syncope, epilepsy, and controls. PMID: 26641207
  48. Data from a population in Sweden suggest association between elevated copeptin plasma levels at time of diagnosis of type 2 diabetes and later development (within 10-12 years) of renal insufficiency and progression to chronic kidney disease stage 3. PMID: 26321369
  49. This study evaluated the relationships among copeptin, ischemia-modified albumin (IMA), and extent of myocardial injury in patients with acute carbon monoxide poisoning. PMID: 26345979
  50. Low serum sodium was associated with an increased risk of cardiovascular and all-cause mortality in type 2 diabetes, but association was not explained by copeptin. PMID: 26201002

Show More

Hide All

Involvement in disease
Diabetes insipidus, neurohypophyseal (NDI)
Subcellular Location
Secreted.
Protein Families
Vasopressin/oxytocin family
Database Links

HGNC: 894

OMIM: 125700

KEGG: hsa:551

STRING: 9606.ENSP00000369647

UniGene: Hs.89648

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1